论文部分内容阅读
目的:研究更昔洛韦对于治疗小儿传染性单核细胞增多症患者的治疗效果及预后分析。方法:选择2012年5月-2015年5月在杭州市萧山区医院接诊的65例小儿传染性单核细胞增多症患者。随机将65例患儿分为观察组和对照组。观察组中患儿每天给予更昔洛韦10mg/kg,加入葡萄糖溶液中,采用静脉注射的方式进行;对照组中患儿每天给予阿昔洛韦10mg/kg,加入葡萄糖溶液中,采用静脉注射的方式进行,7天为1个疗程,同样是连续治疗2个疗程。治疗前后均对患儿进行一系列的血常规检查;在治疗的同时要注意观察记录患儿的体温、咽部症状、肝脾症状及淋巴结回缩情况,并且在治疗期间注意观察有无因药物引起的不良反应,如恶心、呕吐及皮疹等。并且在治疗结束后对治疗效果进行总结分析。结果:观察组中的患儿在接受治疗之后,其发热时间、体温恢复正常的时间、咽峡炎缓解时间、淋巴结缩小时间、肝脾恢复时间都得到了很大程度的缩短;对照组中患儿上述恢复时间虽然有些缩短,但是效果明显不如观察组。从患儿症状恢复时间来看,两组相比差异具有统计学意义(P<0.05)。经过对患儿的一些列血液检查结果分析,观察组中患儿的WBC、异淋、AST、ALT等各项血象指标与治疗前相比,具有很大程度的改善,大部分都已恢复至正常范围;对照组中患儿的各项血象指标与治疗前相比,同样有着一定程度的改善,但是效果不如观察组中的明显,两组相比差异具有统计学意义(P<0.05)。通过对患儿在治疗过程中的不良反应记录分析来看,观察组整体不良反应发生率仅为10.64%,远低于对照组中的36.17%,两组相比差异具有统计学意义(P<0.05)。根据对治疗后患儿治疗效果的评定分析可以得出,观察组整体有效率高达93.94%,远高于对照组中的71.88%,两组相比差异具有统计学意义(P<0.05)。结论:更昔洛韦对于治疗小儿传染性单核细胞增多症具有较好的治疗疗效,并且在保证疗效的同时,患儿发生不良反应的情况要优于其他治疗方式,具有使用价值。
Objective: To study the curative effect and prognosis of ganciclovir in the treatment of children with infectious mononucleosis. Methods: From May 2012 to May 2015, 65 patients with pediatric infectious mononucleosis were admitted to Hangzhou Xiaoshan District Hospital. 65 cases were randomly divided into observation group and control group. Patients in the observation group were treated with ganciclovir 10 mg / kg every day, and added into glucose solution. The patients in the observation group were treated with intravenous injection of acyclovir 10 mg / kg every day. The patients in the control group were given glucose solution by intravenous injection Way, 7 days for a course of treatment, the same treatment is continuous 2 courses. Before and after treatment of children with a series of routine blood tests; in the treatment should be noted at the same time observe the record of children with body temperature, symptoms of throat, liver and spleen symptoms and lymph node retraction, and pay attention to observe whether there is any drug during the treatment Caused by adverse reactions, such as nausea, vomiting and rash. And at the end of treatment for the treatment effect of a summary analysis. Results: After treatment, the children in the observation group had a very shortened time of fever, body temperature returned to normal, angina alleviation time, lymph node reduction time and liver and spleen recovery time. In the control group Although some of the above recovery time shortened, but the effect was significantly less than the observation group. From the recovery time of children with symptoms, the difference between the two groups was statistically significant (P <0.05). After analyzing the results of some blood tests in children, all the blood indexes of WBC, XLS, AST, ALT in the observation group were improved to a great extent compared with those before treatment, and most of them had recovered to The normal range; the control group of children with various blood indicators compared with before treatment, also have a certain degree of improvement, but the effect is not as obvious as the observation group, the difference between the two groups was statistically significant (P <0.05). According to the records of adverse reactions in children during treatment, the overall incidence of adverse reactions in the observation group was only 10.64%, much lower than the 36.17% in the control group, the difference between the two groups was statistically significant (P < 0.05). According to the evaluation of treatment effect in children after treatment, the overall effective rate in the observation group was as high as 93.94%, much higher than that in the control group (71.88%). The difference between the two groups was statistically significant (P <0.05). Conclusion: Ganciclovir has a good therapeutic effect on the treatment of children with infectious mononucleosis. In addition to ensuring the efficacy, ganciclovir is superior to other treatments in adverse reactions, which is of value in use.